BofA analyst Jason Gerberry lowered the firm’s price target on Pfizer (PFE) to $27 from $28 and keeps a Neutral rating on the shares after the company “notably called out” faster COVID-19 product erosion relative to prior guidance as part of its 2026 outlook call. The firm, which “modestly” reduced its 2026 Pfizer sales and EPS estimates and its FY27 EPS estimate following the guidance call, looks to planned obesity data updates from the Metsera acquisition to better understand the company’s potential obesity differentiation.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer Stock (PFE) Resists Lukewarm Update from a Top Analyst
- Pfizer says plans to begin 15 studies in obesity next year
- Pfizer: U.S. government deal to compress margins in 2026
- Pfizer says agreement with U.S. government a ‘critical milestone’
- Pfizer Stock (PFE) Rises despite Weaker 2026 Profit Outlook on Fading COVID-19 Franchise